Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: Results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release

Journal of Medical Economics

Volumn 16, Issue 8, 2013, Pages 987-996

  Rajagopalan, Krithika ^a   O'Day, Ken ^b   Meyer, Kellie ^b   Pikalov, Andrei ^a   Loebel, Antony ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b Xcenda   (United States)

Author keywords

Cost; Economic model; Hospitalization; Lurasidone; Quetiapine; Relapse; Schizophrenia

Indexed keywords

LURASIDONE; PLACEBO; QUETIAPINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST CONTROL; DOUBLE BLIND PROCEDURE; EMERGENCY HEALTH SERVICE; HOSPITAL PATIENT; HOSPITALIZATION COST; HUMAN; MEDICATION THERAPY MANAGEMENT; MENTAL HEALTH CARE; MONOTHERAPY; OBSERVATIONAL STUDY; OUTPATIENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HEALTH SERVICES; HOSPITALIZATION; HUMANS; ISOINDOLES; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; MODELS, ECONOMIC; SCHIZOPHRENIA; THIAZOLES; YOUNG ADULT;

EID: 84880534936     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.809353     Document Type: Article

References (24)

1. Narrow WE, Rae DS, Robins LN, et al. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry 2002;59:115-23
2. Wu EQ, Shi L, Birnbaum H, et al. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med 2006;36:1535-40
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Arlington, VA: American Psychiatric Publishing; 2000
4. Awad AG, Voruganti LNP. The burden of schizophrenia on caregivers. Pharmacoeconomics 2008;26:149-62
5. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9
6. Wier LM, Levit K, Stranges E, et al. HCUP facts and figures: statistics on hospital-based care in the United States, 2008. Rockville, MD: Agency for Healthcare Research and Quality, 2010. http://www.hcup-us.ahrq.gov/reports.jsp. Accessed April 20, 2012
7. Almond S, Knapp M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004;184:346-51
8. Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010;10:2
9. National Institute of Mental Health; Bethesda, MD. Schizophrenia. NIH Publication No. 06-3517. Mental Health Medications 2006;1-25
10. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(Suppl):1-56
11. Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008;100:20-38
12. Peuskens J, Trivedi J, Malyarov S, et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients. Psychiatry 2007;4:34-50
13. Latuda [package insert]. Marlborough, MA: Sunovion Pharmaceuticals Inc, 2011
14. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 2011;65:189-210
15. Stahl SM, Cucchiaro J, Simonelli D, et al. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry. 2013;74:507-1516.
16. Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol 2012;27:165-76
17. Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo-and active-controlled trial. Schizophr Res 2013;145: 101-9
18. Seroquel [package insert]. Wilmington, DE: AstraZeneca, 2011
19. Loebel A, Cucchiaro J, Xu J, et al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month double-blind noninferiority study. Schizophr Res 2013;147:95-102
20. Rajagopalan K, O'Day K, Meyer K, et al. Costs of relapses and relapse-related hospitalizations among adults treated with atypical antipsychotics for schizophrenia. Poster presented at: American Society of Health-System Pharmacists 2012 Summer Meeting & Exhibition; June 9-13, 2012; Baltimore, MD
21. Bureau of Labor Statistics; Washington, DC. Consumer Price Index, All Urban Consumers. USA: US Bureau of Labor Statistics. http://data.bls.gov/cgi- bin/surveymost?cu. Accessed October 3, 2011
22. Singh G, Mannalithara A, Rajagopalan K, et al. Incremental treatment costs in hospitalized schizophrenia patients with comorbid type 2 diabetes mellitus. Poster presented at: American Society of Health-System Pharmacists 2012 Summer Meeting & Exhibition; June 9-13, 2012; Baltimore, MD
23. RED BOOK Online. Micromedex 2.0. Thomson Reuters. http://www. micromedexsolutions. com Accessed October 9, 2012
24. Citrome L. Lurasidone in schizophrenia: new information about dosage and place in therapy. Adv Ther 2012;29:815-25